Oral Prednisone is NOT Recommended for Routine Treatment of Osteoarthritis
Oral prednisone should not be used as a standard treatment for osteoarthritis. While the FDA label indicates prednisone is approved for "synovitis of osteoarthritis" and "post-traumatic osteoarthritis" 1, major clinical practice guidelines consistently omit oral corticosteroids from their recommended treatment algorithms for OA management, recommending only intra-articular corticosteroid injections instead 2.
Guideline Recommendations
The NICE guidelines (2008) provide a clear treatment hierarchy for osteoarthritis that does not include oral corticosteroids 2. The recommended pharmacological approach is:
- First-line: Paracetamol (acetaminophen) and/or topical NSAIDs 2
- Second-line: Oral NSAIDs or COX-2 inhibitors (with proton pump inhibitor) 2
- For acute flares: Intra-articular corticosteroid injections for moderate to severe pain 2
The EULAR guidelines (2000,2003) similarly recommend intra-articular steroid injections for acute exacerbations, especially with effusion, but do not recommend oral corticosteroids 2. The 2019 ACR/Arthritis Foundation guideline made strong recommendations for intra-articular glucocorticoid injections for knee OA but did not recommend oral corticosteroids 2.
Limited Research Evidence
While two recent randomized controlled trials showed some benefit of low-dose oral prednisone in OA:
- Knee OA study (2014): 7.5 mg/day prednisone for 6 weeks reduced pain (mean difference 10.9 mm on VAS), improved function, and reduced systemic inflammation markers, with effects sustained at 12 weeks 3
- Hand OA study (2019): 10 mg/day prednisone for 6 weeks reduced finger pain by 16.5 mm more than placebo in patients with inflammatory signs 4
However, these studies involved highly selected patients with signs of inflammation and short treatment durations. Earlier animal studies showed conflicting results, with one study suggesting protective effects at 0.3 mg/kg/day 5 but another showing no benefit at the lower dose of 0.1 mg/kg/day 6.
Critical Safety Concerns
The FDA label for prednisone includes extensive warnings about adverse effects that are particularly concerning in the elderly OA population 1:
- Osteoporosis risk: Corticosteroids decrease bone formation and increase bone resorption, potentially worsening the underlying skeletal problems in OA patients 1
- Infection susceptibility: Increased risk of bacterial, viral, fungal, and parasitic infections 1
- Cardiovascular and metabolic effects: Sodium retention, edema, hypertension, hyperglycemia 1
- Adrenal suppression: Risk of secondary adrenocortical insufficiency with prolonged use 1
- Gastrointestinal complications: Increased risk of peptic ulcers and GI perforation 1
Clinical Bottom Line
Use intra-articular corticosteroid injections instead of oral prednisone for OA flares. Intra-articular injections provide effective short-term pain relief (effect size 1.27 at 7 days) with fewer systemic side effects 2. They are particularly beneficial for acute exacerbations with effusion 2.
For sustained OA management, prioritize:
- Core treatments: exercise, weight loss (if overweight), patient education 2
- Pharmacological options: paracetamol, topical NSAIDs, then oral NSAIDs with gastroprotection 2
- Intra-articular corticosteroids for flares only, not chronic use 2
The risk-benefit ratio of chronic oral corticosteroid use does not favor its routine use in OA, given the availability of safer alternatives and the significant potential for adverse effects in this predominantly elderly population 1, 7, 8.